Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's SyndromeBusiness Wire • 01/31/22
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndromePRNewsWire • 01/13/22
Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual ConferenceBusiness Wire • 01/06/22
Moderna's on the Rise, but This Small Biotech Is the Nasdaq's Big Winner on New Year's EveThe Motley Fool • 12/31/21
Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatmentMarket Watch • 12/31/21
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's SyndromeBusiness Wire • 12/30/21
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris PharmaBusiness Wire • 12/16/21
Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other HighlightsBusiness Wire • 11/10/21
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021Business Wire • 11/02/21
Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 11/01/21